Clinical trials: Locally Advanced Gastric Carcinoma
Gastric Adenocarcinoma, Stage II Gastric Cancer
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction.
- Conditions
- Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
- Trial name
- NCT00062374
- Testing
- Cisplatin, Computed Tomography, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or…
- Trial name
- NCT02514551
- Testing
- Ramucirumab, Paclitaxel
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy of ipatasertib in combination with oxaliplatin, 5-fluorouracil, and leucovorin (modified FOLFOX6 [mFOLFOX6]) chemotherapy in…
- Trial name
- NCT01896531
- Testing
- 5-Fluorouracil, Ipatasertib, Leucovorin
- Where
- 34 sites in United States, France and 9 more
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Esophageal Cancer, Gastric Cancer
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments.
- Trial name
- NCT00737438
- Testing
- epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasm, Gastrointestinal
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and physician's choice treatment in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed…
- Trial name
- NCT03329690
- Testing
- DS-8201a, Physician's Choice
- Where
- 66 sites in Japan, South Korea
- Volunteers
- 233 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
This randomized phase II trial studies how well docetaxel, oxaliplatin, capecitabine, fluorouracil, and radiation therapy works compared with fluorouracil when given together with oxaliplatin and radiation therapy in treating…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00938470
- Testing
- capecitabine, docetaxel, fluorouracil
- Where
- 187 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
This was a Phase 1, open-label, dose-escalation trial of avelumab (antibody targeting programmed death ligand 1 [anti PD-L1]) in Japanese participants with metastatic or locally advanced solid tumors, followed by a consecutive…
- Trial name
- NCT01943461
- Testing
- Avelumab 3 mg/kg, Avelumab 10 mg/kg, Avelumab 20 mg/kg
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gastric Cancer, Chemotherapy Effect
Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Safety and efficacy study of neoadjuvant chemotherapy (FLOT versus SOX) for gastric cancer patients in high volume center of China
- Trial name
- NCT03636893
- Testing
- FLOT Chemotherapy, SOX Chemotherapy
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Ruijin Hospital
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
This phase Ib/II trial studies the side effects and best way to give pembrolizumab with combination chemotherapy and radiation therapy before surgery and to see how well it works in treating adult patients with gastroesophageal…
- Conditions
- Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7
- Trial name
- NCT02730546
- Testing
- Carboplatin, Computed Tomography, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Mayo Clinic
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior…
- Trial name
- DG-06 (NCT04989816)
- Testing
- Trastuzumab Deruxtecan
- Where
- 24 sites in China
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
This randomized phase II trial studies how well fludeoxyglucose F-18 (FDG)/positron emission tomography (PET) directed treatment improves response in patients with stomach or gastroesophageal junction cancer that has not spread…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer
- Trial name
- NCT02485834
- Testing
- FDG-PET, surgery, 5-FU
- Where
- 71 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stomach Neoplasms
Docetaxel and Oxaliplatin in Gastric Cancer
This phase II study addressed the use of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced…
- Trial name
- NCT00382720
- Testing
- Docetaxel + Oxaliplatin, Docetaxel + Oxaliplatin + 5-FU, Docetaxel + Oxaliplatin + Capecitabine
- Where
- 12 sites in United States, Belgium and 10 more
- Volunteers
- 275 people
- Sponsor
- Sanofi
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- Spotlight (NCT03504397)
- Testing
- zolbetuximab, oxaliplatin, folinic acid
- Where
- 218 sites in United States, Australia and 18 more
- Volunteers
- 565 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Stage T3-4NxM0 Gastric Cancer
Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Thymidylate Synthase (TS) is a key enzyme in the synthesis of DNA and the target enzyme inhibited by 5-fluorouracil (5-FU). TS level in the tumour cells has been reported as predictive to response to 5-FU and a prognostic factor…
- Trial name
- NCT00414271
- Testing
- Docetaxel, Capecitabine
- Where
- Singapore
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Cancer, Gastric Cancer
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00217581
- Testing
- Bevacizumab, Docetaxel, Oxaliplatin
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene